and today. two Andrew morning, will good I everyone. topics Thanks, cover
discuss of quarter clinical in fourth a cancer of Phase trial updated First, on two last our on initiated initial the trials mentioned X of programs in pivotal the with year. the those that Phase each new will Jack and and we I timing X the colorectal focus results
will data. medical our on efforts, including published recently and some provide of some an upcoming new Second, I update
the As patients press to trial results first-line you read trial and or we have first-line every myelotoxic are metrics we the release, this two on our extension timing based cancer, from XX-day bevacizumab, trilaciclib for with chemotherapy containing efficacious in ongoing cancer. is FOLFOXIRI receiving trilaciclib enrollment accelerated morning an X, prior This a consecutive line administered highly XXX in PRESERVE of placebo given initial regimen but seeing, days our in colorectal of pivotal approximately of the colorectal cycle.
chemotherapeutic is our in most benefits other a damage, this XFU, bone less infusion Unlike the earlier showing of other results generated As XX-hour a in trial reminder, that than results first clinical this Excitement the key high work since initiated progression-free the early backbone. the myeloprotection is of our side regimen. given of in And secondary has we team, survival. preclinical to of excellent next the overall survival chemotherapy-induced trilaciclib the myelotoxic which been are sites words, to protecting endpoints by as of initial data at were endpoint mylosuppressive ongoing multi-lineage and trials, quarter stated. from And we and include this our effects the with initial in primary our projecting study. marrow which announce thanks year, previously is
study additional the expect enrolled last soon, in that at We the and we’ll announce information patient to point. be
being discuss Phase the last with trial potential of an antibody-drug combination trials or quarter. designed I’ll Patients II Next, Starting we the the Trodelvy, to conjugate, with additive initiated ADC. two new evaluate are treated it to XX-patient chemotherapeutic conjugated. prior is one the and until tumor payload a ADCs XX-day on days disease to eight progression that with which by delivered consist antibody of the to trilasitib the of administered cycle is Trodelvy. trilaciclib
via can cytotoxic the targeted they payload. chemotherapy of ADCs considered cells effect such, kill cancer since the be As
are a but that As shown gemcitabine given could highly two trilaciclib in carry benefits ADC. significant effective Therefore, can efficacy of myelosuppression. of carboplatin improve there TNBC. chemotherapy be they X in combining already a our prior cytotoxic within We’ve trilaciclib, also we with can trial risk to potential Phase result,
the and second enhancing cytotoxic is myelosuppression. is increasing antitumor efficacy killing, first reducing The by by
Tregs including approximately while The tumor endpoints of trilaciclib are for checkpoint or cells patients treatment understanding trial to to to important system overall XX fourth action from CDX+ trial T in response in a without We the clinical by an assess breast that and suppressing has of cells to trilaciclib inhibitor. of from of ratio cells preclinical of with this the neoadjuvant modulate of who eligible This duration. rate year. designed to primary receive ability the study is preferentially prior triple-negative initial expect is the this confirm endpoint microenvironment. immune suppressor immune-based We Phase to know potential quarter the this ratio T the allowing CDX+ the action increase for proliferation of its in mechanism our will a cancer. mechanism have longer X and T data myeloprotection results The trial, and regulatory
more set immunity quarter We also the should changes across be next immune These identify of combinations. will fourth in studies help of trial cancer year. evaluating types Initial data this the multiple this broadly results from also the tumor cycle. expected us across are and treatment
This in checkpoint bladder that new trilaciclib of expected backbone also and year. you I including the results, concomitant response with trial. inhibitor. Phase same X, endpoints the successful of overall suggests study used this chemotherapy add have X in we will rate TNBC could are addition, chemotherapy study Phase PRESERVE that trilaciclib avelumab inhibitor, is to a remind with In utilizing late a mechanism first-line also generated and X previous the immune initial our And efficacy our myeloprotection cancer checkpoint from patients
PRESERVE in I’ll we Phase follow the designed on our in setting. triple-negative Finally, our up trial breast on cancer, touch trial pivotal that X X, survival saw in signal exciting to
We have important recently the two made protocol. to changes
second-line to this the clinical potential discontinued commercial to a we cancer has this of First, this Trodelvy caused trial enrollment setting, second-line in study to have that the arm of rapid paradigm in by the shift triple-negative in created second-line the uptake in metastatic treatment setting. the and significant breast barriers cohort for which due of
from inhibitor second cancer patients Research, important pembrolizumab population. two previously who the HEOR. checkpoint of the gets triple-negative arm experience first-line in team clinical We’ve neoadjuvant are adjuvant among in of enrollment breast medical common wants questions into Initial of for affairs, and half this trial the received develop Economics have allow and to the recently published that regarding topics will we data the available studies the of patient to or on our Second, Health be topic. Outcomes will trial Changing that treatment this XXXX.
per trilaciclib the the first-line adverse issue a showing cancer. analysis. that Journal utilizing perspective NCCN the January $XX,XXX the over of mentioning costs this patients. associated over events Conference myelosuppressive of the savings Pharmacy recent according of trilaciclib the practice neutropenia, resulted and of was Integra was use compelling U.S. estimated second & lung publication the that in impact use trilaciclib for The in with first savings included of A the adverse events, fewer number from were edition Medical at $XXX,XXX. five due trilaciclib of fibro in the cost Care extensive more cost patients small period use conclude I’ll of a The scenario results in December by associated savings a Journal myelosuppressive we cell presenting thrombocytopenia of cost estimated The compared chemotherapy for the to over XXX years including first of to described five-year stage March. cost-effectiveness neutropenia, data prior and describe anemia myelosuppression. in that data a accepted without and of to was to upcoming abstract Economics of estimated are patient reduce Specialty than treatment The Managed in data to study their our with real-world that COSELA payer burden
Jen? the full with look for have added they who are the for of data of call to since forward and quarter these a Jen However, review sharing commercial COSELA, turn With from whom real-world that, you patients. results once the I’ll We have over are presented. year received fourth XXXX. data we financial of patients to most
